Andrew Cheng is President and CEO of Akero Therapeutics, Inc.. Currently has a direct ownership of 605,417 shares of AKRO, which is worth approximately $18.5 Million. The most recent transaction as insider was on Dec 02, 2024, when has been sold 25,000 shares (Common Stock) at a price of $32.09 per share, resulting in proceeds of $802,250. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 605K
0% 3M change
9.57% 12M change
Total Value Held $18.5 Million

Andrew Cheng Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 02 2024
SELL
Open market or private sale
$802,250 $32.09 p/Share
25,000 Reduced 3.97%
605,417 Common Stock
Dec 02 2024
BUY
Exercise of conversion of derivative security
$527,500 $21.1 p/Share
25,000 Added 3.81%
630,417 Common Stock
Nov 01 2024
SELL
Open market or private sale
$3,466,628 $31.99 p/Share
108,366 Reduced 15.18%
605,417 Common Stock
Nov 01 2024
BUY
Exercise of conversion of derivative security
$2,286,522 $21.1 p/Share
108,366 Added 14.63%
632,503 Common Stock
Oct 18 2024
SELL
Open market or private sale
$2,022,446 $31.83 p/Share
63,539 Reduced 9.5%
605,417 Common Stock
Oct 18 2024
BUY
Exercise of conversion of derivative security
$1,340,672 $21.1 p/Share
63,539 Added 8.67%
668,956 Common Stock
Oct 17 2024
SELL
Open market or private sale
$96,565 $31.12 p/Share
3,103 Reduced 0.51%
605,417 Common Stock
Oct 17 2024
BUY
Exercise of conversion of derivative security
$65,473 $21.1 p/Share
3,103 Added 0.51%
608,520 Common Stock
Oct 16 2024
SELL
Open market or private sale
$778,250 $31.14 p/Share
24,992 Reduced 3.96%
605,417 Common Stock
Oct 16 2024
BUY
Exercise of conversion of derivative security
$527,331 $21.1 p/Share
24,992 Added 3.81%
630,409 Common Stock
Sep 10 2024
SELL
Open market or private sale
$45,500 $26.18 p/Share
1,738 Reduced 0.29%
605,417 Common Stock
Aug 16 2024
BUY
Exercise of conversion of derivative security
$15,213 $0.62 p/Share
24,538 Added 3.88%
607,155 Common Stock
Jun 28 2024
BUY
Grant, award, or other acquisition
$21,216 $19.94 p/Share
1,064 Added 0.18%
582,617 Common Stock
Jun 11 2024
SELL
Open market or private sale
$178,720 $22.64 p/Share
7,894 Reduced 1.34%
581,553 Common Stock
Mar 13 2024
SELL
Open market or private sale
$55,781 $28.33 p/Share
1,969 Reduced 0.33%
589,447 Common Stock
Mar 04 2024
SELL
Open market or private sale
$2,549,250 $33.99 p/Share
75,000 Reduced 11.25%
591,416 Common Stock
Mar 04 2024
BUY
Exercise of conversion of derivative security
$1,391,250 $18.55 p/Share
75,000 Added 10.12%
666,416 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$24,800 $0.62 p/Share
40,000 Added 6.34%
590,911 Common Stock
Dec 14 2023
SELL
Open market or private sale
$33,797 $20.76 p/Share
1,628 Reduced 0.29%
550,911 Common Stock
Dec 11 2023
SELL
Open market or private sale
$148,248 $20.02 p/Share
7,405 Reduced 1.32%
552,539 Common Stock
Dec 11 2023
BUY
Exercise of conversion of derivative security
$47,095 $6.36 p/Share
7,405 Added 1.31%
559,944 Common Stock
Dec 08 2023
SELL
Open market or private sale
$257,588 $20.01 p/Share
12,873 Reduced 2.72%
460,998 Common Stock
Dec 08 2023
BUY
Exercise of conversion of derivative security
$81,872 $6.36 p/Share
12,873 Added 2.64%
473,871 Common Stock
Dec 08 2023
BUY
Grant, award, or other acquisition
-
91,541 Added 14.21%
552,539 Common Stock
Dec 07 2023
SELL
Open market or private sale
$134,134 $20.02 p/Share
6,700 Reduced 1.43%
460,998 Common Stock

Also insider at

VERA
Vera Therapeutics, Inc. Healthcare
ABUS
Arbutus Biopharma Corp Healthcare
AC

Andrew Cheng

President and CEO
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO